This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aghi, M., Kramm, C.M., Chou, T.-C., Breakefield, X.O., and Chiocca, E.A., 1998, Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies, J. Natl. Cancer Inst. 90:370–380.
Akbar, A.N., and Salmon, M., 1997, Cellular environments and apoptosis: tissue microenvironments control activated T-cell death, Immunol Today 18:72–76.
Anderson, W.F., 1998, Human gene therapy, Nature 392:25–30.
Azuma, M., Cayabyab, M., Buck, D., Phillips, J.H., and Lanier, L.L., 1992, Involvement of CD28 in MHC-unrestricted cytotoxicity mediated by a human natural killer leukemia cell line, J. Immunol. 149: 1115–1123.
Cayeux, S., Beck, C., Aicher, A., Dörken, B., and Blankenstein, T., 1995, Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines, Eur. J. Immunol. 25:2325–2331.
Cayeux, S., Beck, C., Dörken, B., and Blankenstein, T., 1996, Coexpression of interleukin-4 and B7.1 in murine tumor cells leads to improved tumor rejection and vaccine effect compared to single gene transfectants and a classical adjuvant, Hum. Gene Ther. 7:525–529.
Cayeux, S., Richter, G., Becker, C., Beck, C., Aicher, A., Pezzutto, A., Dörken, B., and Blankenstein, T., 1997, Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency, Eur. J. Immunol. 27:1657–1662.
Chen, L., McGowan, P., Ashe, S., Johnston, J., Li, Y, Hellström, I., and Hellström, K.E., 1994, Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity, J. Exp. Med. 179:523–532.
Chen, P.W., Geer, D.C., Podack, E.R., and Ksander, B.R., 1996, Tumor cells transfected with B7-1 and interleukin-12 cDNA induce protective immunity, Ann. N. Y. Acad. Sci. 795:325–327.
Chong, H., Todryk, S., Hutchinson, G., Hart, I.R., and Vile, R.G., 1998, Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local antitmour response and may generate systemic protective immunity, Gene Ther. 5:223–232.
Chouaib, S., Asselin-Paturel, C., Mami-Chouaib, F, Caignard, A., and Blay, J.Y., 1997, The host-tumor immune conflict: from immunosuppression to resistance and destruction, Immunol. Today 18:493–497.
Daniel, P.T., Kroidl, A., Cayeux, S., Bargou, R., Blankenstein, T, and Dörken, B., 1997, Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis, J. Immunol. 159:3808–3815.
Emtage, P.C.R., Wan, Y, Bramson, J.L., Graham, F.L., and Gauldie, J., 1998, A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model, J. Immunol. 160:2531–2538.
Foa, R., Guarini, A., and Gansbacher, B., 1992, IL2 treatment for cancer: from biology to gene therapy, Br. J. Cancer 66:992–998.
Gäken, J.A., Hollingsworth, S.J., Hirst, W.J.R., Buggins, A.G.S., Galea-Lauri, J., Peakman, M., Kuiper, M., Patel, P., Towner, P., Patel, P.M., Collins, M.K.L., Mufti, G.J., Farzaneh, F, and Darling, D.C., 1997, Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4+-mediated rejection of established tumors, Hum. Gene Ther. 8:477–488.
Galea-Lauri, J., Farzaneh, F., and Gäken, J., 1996, Novel costimulators in the immune gene therapy of cancer, Cancer Gene Ther. 3:202–213.
Galea-Lauri, J., Darling, D., Kuiper, M., Gäken, J., Souberbielle, B., and Farzaneh, F., 1998, Expression of a variant CD28 on a sub-population of human NK cells: implications for B7-mediated stimulation of NK cells, J. Immunol.
Hollingsworth, S.J., Darling, D., Gäken, J., Hirst, W., Patel, P., Kuiper, M., Towner, P., Humphreys, S., Farzaneh, F., and Mufti, G.J., 1996, The effect of combined expression of interleukin 2 and interleukin 4 on the tumorigenicity and treatment of B16F10 melanoma, Br. J. Cancer 74:6–15.
Huang, A.Y.C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D, and Levitsky, H., 1994, Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens, Science 264:961–965.
Huang, A.Y.C., Bruce, A.T., Pardoll, D.M., and Levitsky, H.I., 1996, Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med. 183:769–776.
Kato, K., Okumura, K., and Yagita, H., 1997, Immunoregulation by B7 and IL-12 gene transfer, Leukemia 11:572–576.
Koberda, J., Grimm, E.A., and Moser, R.P., 1993, Effect of anti-CD3/anti-CD28/interleukin-2 stimulation of mononuclear cells on transforming growth factor β inhibition of lymphokine-activated killer cell generation, J. Cancer Res. Clin. Oncol 119:131–136.
Lieschke, G.J., Rao, P.K., Gately, M.K., and Mulligan, R.C., 1997, Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo, Nat. Biotechnol 15:35–40.
Mackensen, A., Lindemann, A., and Mertelsmann, R., 1997, Immunostimulatory cytokines in somatic cells and gene therapy of cancer, Cytokine Growth Factor Rev. 8:119–128.
Martinotti, A., Stoppacciaro, A., Vagliani, M., Melani, C., Spreafico, F, Wysocka, M., Parmiani, G., Trinchieri, G., and Colombo, M.P., 1995, CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes, Eur. J. Immunol. 25:137–146.
Matulonis, U., Dosiou, C., Freeman, G., Lamont, C, Mauch, P., Nadler, L.M., and Griffin, J.D., 1996, B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J. Immunol. 156:1126–1131.
Musiani, P., Modesti, A., Giovarelli, M., Cavallo, F., Colombo, M.P., Lollini, P.L., and Forni, G., 1997, Cytokines, tumour-cell death and immunogenicity: a question of choice, Immunol. Today 18:32–36.
Nandi, D., Gross, J.A., and Allison, J.P., 1994, CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells, J. Immunol. 152:3361–3369.
Nanni, P., Rossi, I., De Giovanni, C., Landuzzi, L., Nicoletti, G., Stoppacciaro, A., Parenza, M., Colombo, M.P., and Lollini, P.-L., 1998, Interleukin 12 gene therapy of MHC-negative murine melanoma metastases, Cancer Res. 58:1225–1230.
National Institutes of Health, 1998, Bethesda (July 20, 1998); http://www.nih.gov/od/orda/protocol.htm.
Nishimura, T., Watanabe, K., Yahata, T., Uede, T., Saiki, L, Herrmann, S.H., Kobayashi, M., and Habu, S., 1996, The application of IL-12 to cytokine therapy and gene therapy for tumors, Ann. N. Y. Acad. Sci. 795:375–378.
O’Malley, B.W., Cope, K.A., Chen, S.-H., Li, D., Schwartz, M.R., and Woo, S.L.C., 1996, Combination gene therapy for oral cancer in a murine model, Cancer Res. 56:1737–1741.
Parmiani, G., 1998, Gene modified human melanoma cell vaccines: new strategies, in: Eurocancer 98. Compte rendu du XI congrès, (M. Boiron, and M. Marty, eds.), p. 299, John Libbey Eurotext, Paris.
Pizzoferrato, E., Chu, N.R., Hawley, T.S., Lieu, F.H.L., Barber, B.H., Hawley, R.G., Watts, T.H., and Berinstein, N.L., 1997, Enhanced immunogenicity of B cell lymphoma genetically engineered to express both B7-1 and interleukin-12, Hum. Gene Ther. 8:2217–2228.
Pützer, B.M., Hitt, M., Muller, W.J., Emtage, P., Gauldie, J., and Graham, F.L., 1997, Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression, Proc. Natl. Acad. Sci. USA 94:10889–10894.
Salvadori, S., Gansbacher, B., Wernick, I., Tirelli, S., and Zier, K., 1995, B7-1 amplifies the response to interleukin-2-secreting tumor vaccines in vivo, but fails to induce a response by naive cells in vitro, Hum. Gene Ther. 6:1299–1306.
Schwartz, R.H., 1992, Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy, Cell 71:1065–1068.
Tahara, H., Zitvogel, L., Storkus, W.J., Zen, H.J., McKinney, T.G., Schreiber, R.D., Gubler, U, Robbins, P.D., and Lotze, M.T., 1995, Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector, J. Immunol. 154:6466–6474.
Tahara, H., and Lotze, M.T., 1995, Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther. 2:96–106.
Zier, K., Gansbacher, B., and Salvadori, S., 1996, Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy, Immunol. Today 17:39–45.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Kluwer Academic Publishers
About this chapter
Cite this chapter
Kuiper, M., Sanches, R., Bignon, YJ., Farzaneh, F. (2002). B7.1 and Cytokines. In: Habib, N.A. (eds) Cancer Gene Therapy. Advances in Experimental Medicine and Biology, vol 465. Springer, New York, NY. https://doi.org/10.1007/0-306-46817-4_33
Download citation
DOI: https://doi.org/10.1007/0-306-46817-4_33
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-306-46191-0
Online ISBN: 978-0-306-46817-9
eBook Packages: Springer Book Archive